Publication

Article

Digital Edition

Ophthalmology Times: April 15, 2021
Volume46
Issue 7

Preferred practice pattern guidelines help identify POAG but are not always followed

Author(s):

Investigators determine that patient rates of adherence with gonioscopy are low.


Reviewed by Ali A. Al-Rajhi, PhD, MPH

The American Academy of Ophthalmology (AAO) developed Preferred Practice Pattern guidelines (PPPs) to help ophthalmologists not specialized to identify primary open-angle glaucoma (POAG).

The POAG PPP recommends a gonioscopy be performed periodically to document the status of the angle to facilitate the documentation of POAG.

However, a check of the adherence with this recommendation indicated that most patients have not had a gonioscopy and that more than 25% of those who did not were likely to have an IOP that was higher than those who did undergo a gonioscopy, according to Ali A. Al-Rajhi, PhD, MPH, manager of guidelines and policy at the American Academy of Ophthalmology in San Francisco, California.

Related: Looking at real-world trial data replication outcomes of IRIS Registry data

If left unchecked, POAG can result in loss of the optic nerve rim and retinal nerve fiber layer with associated visual field defects.

Risk factors include, but are not limited to, older age, Black/African race, Latino/Hispanic ethnicity, and elevated IOP.

“It is one thing to publish evidence recommendations, but it is another to measure compliance with the recommendations,” Al-Rajhi said.

Al-Rajhi pointed out that there are limited epidemiologic data regarding assessment of the demographic characteristics of patients with POAG who did and did not adhere to the POAG PPP’s gonioscopy recommendation.


Shedding light on patient adherence

Al-Rajhi and his colleagues set out to determine the adherence rate and characteristics of patients with POAG who were adherent in a retrospective cohort study. They theorized that most patients were nonadherent.

Related: Linking patient imaging data to AAO IRIS Registry


The investigators used the extensive AAO IRIS (Intelligent Research in Sight) Registry for the study.

The goal was to identify patients adherent to gonioscopy during the study period from January 1, 2013, to December 31, 2018, and to evaluate IOP outcomes 12 months after POAG was diagnosed.

The patients were defined as gonioscopy adherent if they underwent a gonioscopy within 12 months of the initial diagnosis of POAG.

The results showed that of the 1,967,087 patients with POAG, 414,489 (21%) underwent a gonioscopy within 1 year after diagnosis; 54% of women and 46% of men were adherent. The average time to gonioscopy was about 59 days.

Younger patients and Asian, Black/Asian and Latino/Hispanic patients were significantly more likely to undergo a gonioscopy compared with Caucasian patients (P < .0001 for all comparisons), Al-Rajhi said.

Related: Eliminating the potential land mines in glaucoma surgery

Assessment of IOP, specifically 18 mm Hg or lower and higher than 18 mm Hg following the POAG diagnosis, showed that Asian and Latino/Hispanic patients were significantly (P < .001 for both comparisons) less likely to have an IOP exceeding 18 mm Hg at 12 months compared with Hispanic patients.

In addition, those patients with a baseline IOP over 18 mm Hg who did not have a gonioscopy were more likely to have an IOP over 18 mm Hg at 12 months (P < .001 for both comparisons).

More than three-quarters (79%) of the study patients did not undergo a gonioscopy within 12 months of the earliest diagnosis of POAG and were 26% more likely to have an IOP that was higher compared with those who did have a gonioscopy at 12 months.

The factors that were associated with adherence with gonioscopy were younger age and Asian, Black/African, and Latino/Hispanic ethnicity. Lower IOPs were associated with Asian and Latino/Hispanic ethnicity, Al-Rajhi concluded.

Related: Drainage device offers IOP lowering capabilities at 1 year

Ophthalmologists and the public are invited to access, at no cost, PPPs for this and other ocular diseases at AAO.org/ppp.

--

Ali Al-Rajhi, PhD, MPH
e:alrajhi@stanford.edu
This article is adapted from Al-Rajhi’s presentation at the American Academy of Ophthalmology’s 2020 virtual annual meeting. Al-Rajhi has no financial interest in this subject matter.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.